Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post by NEJM on X, adding:
“Phase 3 WU-KONG28: 1L Sunvozertinib v Chemotherapy in EGFR Exon 20 NSCLC
- mPFS 10.3 v 7.5 mos (HR 0.65)
- ORR ~60% v 30%
Keep in mind, 1L PAPILLON (Amivantamab + chemo) is currently our SOC (mPFS 11.4 mos, ORR of 73%).”
Quoting NEJM’s post:
“Presented at ASCO26: In NSCLC with EGFR exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia.”
Title: First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
Authors: Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M. Memmott, Ozan Yazici, Meili Sun, Catherine Shu, Elvire Pons-Tostivint, Yun Fan, Gonzalo Fernandez-Hinojal, Elaine Shum, Mengzhao Wang, Federica Bertolini, D. Ross Camidge, Chengzhi Zhou, Ludovic Doucet, Qunying Hong, Jian Fang, Dingzhi Huang, Bo Jin, Yan Yu, Lorenzo Antonuzzo, Denis Moro-Sibilot, Jaafar Bennouna, Gilberto de Castro Jr., Li Zheng, John V. Heymach
Read the Full Article.
Other Articles Featuring Eric Singhi On OncoDaily.